Asset Details
Do you wish to reserve the book?
Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder
Do you wish to request the book?
Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Aripiprazole as Adjunctive Therapy for Patients with Major Depressive Disorder
2011
Overview
Aripiprazole was initially approved to treat schizophrenia and later approved for bipolar mania, as a monotherapy and an adjunctive therapy (manic or mixed episodes), and for irritability associated with autism. Aripiprazole is a partial agonist at dopamine D
2
and D
3
and serotonin 5-HT
1A
receptors, and is an antagonist at 5-HT
2a
receptors. This profile, and convincing preliminary data from small-scale studies, provided the rationale for the large-scale exploration of aripiprazole for unipolar depression. Recently, three 6-week, large-scale, randomized, double-blind, placebo-controlled clinical trials demonstrated clinically meaningful efficacy for aripiprazole as an adjunctive therapy to antidepressants for treating major depressive disorder (MDD). In November 2007, aripiprazole was approved by the US FDA as an adjunctive therapy to antidepressants for treating MDD, with support from two of the above-mentioned trials. In the trials, aripiprazole was demonstrated to be safe and well tolerated, and showed a minimal trend for weight gain over the course of a 6-week treatment. The incidence of akathisia was higher than that reported in studies of patients with schizophrenia; however, most cases were mild to moderate and infrequently lead to discontinuation (5/1090 from all three trials).
This comprehensive review provides an overview of the data from all three 6-week studies (including a pooled analysis) and from an unpublished 52-week, open-label extension study, to inform physicians and facilitate reasonable treatment decisions. In addition, specific issues associated with the use of aripiprazole as an adjunctive therapy in patients with MDD, including possible early treatment effect, appropriate timing of therapy initiation, appropriate dosing and duration of treatment, possible differential effect on depressive subgroups and long-term tolerability, are also discussed.
Publisher
Springer International Publishing,Adis International,Wolters Kluwer Health, Inc
Subject
Adult and adolescent clinical studies
/ Animals
/ Biological and medical sciences
/ Complications and side effects
/ Depressive Disorder, Major - drug therapy
/ Humans
/ Medicine
/ Pharmacology. Drug treatments
/ Piperazines - administration & dosage
/ Piperazines - adverse effects
/ Piperazines - pharmacokinetics
/ Piperazines - therapeutic use
/ Psycholeptics: tranquillizer, neuroleptic
/ Psychology. Psychoanalysis. Psychiatry
/ Quinolones - administration & dosage
/ Quinolones - adverse effects
/ Quinolones - pharmacokinetics
